Compound · clinical trials

FXS5626 clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our China register that name FXS5626 as an intervention. Synced 3 Nov 2026

2Current trials

2Recruiting now

1Lead sponsor

1Country register

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 3 Nov 2026 · Editorial standards

At a glance

FXS5626 is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. The most-studied condition is Active Non-anterior, Non-infectious Uveitis.

Patient leaflets for FXS5626

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Recruiting2100%

Trials by phase

Phase 2150%
Phase 1150%

Clinical trials of FXS5626

2 trials

Study	Phase	Status	Lead sponsor	Registers
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU NCT07552012 · ClinicalTrials.gov ↗ · Active Non-anterior, Non-infectious Uveitis	Phase 2	Recruiting	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd	China
QT Interval Effects Study of Oral FXS5626 Tablets NCT07695779 · ClinicalTrials.gov ↗ · Evaluation of QTc Interval	Phase 1	Recruiting	Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with FXS5626

2 conditions

Active Non-anterior, Non-infectious Uveitis1Evaluation of QTc Interval1

By country register

Register	Trials	Recruiting
Clinical trials in China	2	2

A trial with sites in more than one country appears in each of those registers.

Questions about FXS5626 trials

How many clinical trials are testing FXS5626?

2 current trials in our China register name FXS5626 as a drug or biological intervention, as of the registry sync on 3 November 2026. Completed and withdrawn studies are not counted.

Are FXS5626 trials recruiting patients?

Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors FXS5626 clinical trials?

The lead sponsor is Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how FXS5626 works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how FXS5626 works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists FXS5626 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 3 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.